Treatment of Topical Ketorolac Gel in Acute Gouty Flare

Inclusion Criteria: Cohorts 1 and 2 * Evidence of a personally signed and dated informed consent form (ICF) in English * Healthy study participants who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures, * Body mass index (BMI) from 18.0 to 32.0 kg/m2, inclusive; and body weight of at least 50 kg (110 lbs) and Resting supine systolic blood pressure from 90 to 140 mmHg and supine diastolic blood pressure from 40 to 90 mmHg * Male participants must agree to utilize a barrier contraceptive method for the duration of the study and agree to avoid sperm donation for at least 90 days after completing study participation and female participants must be of non-childbearing potential (defined as either surgically sterile or at least 1 year post-menopausal; post- menopausal is defined as no menses for 12 months and confirmed by FSH level ≥ 40 mIU/mL); or must be using a highly effective method of contraception Cohort 3 - additional requirements \- Medical diagnosis of gout for at least 2 years and1 - 2 acute gout flare-ups within the last 12 months Exclusion Criteria: Cohorts 1. 2 and 3 * Presence or history of any disorder that may prevent the successful completion of Cohort 1 \[or Cohort 2, as appropriate\] * Allergy or sensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), ketorolac tromethamine, or any components of the formulation and /or history of significant allergies and hypersensitivity reactions (h…